Key Highlights

  • Revenue was USD 12.87 million against an estimate of USD 14.27 million.
  • Loss per share was USD 0.42 against an estimate of a USD 0.36 loss.
  • Net loss was USD 94.78 million for the quarter.
  • Cash and cash equivalents were USD 530.6 million at September 30.

Ocular Therapeutix (NASDAQ:OCUL) reported third quarter 2026 net product Revenue of USD 12.87 million, against an estimate of USD 14.27 million. The loss per share was USD 0.42, compared with an estimate of a USD 0.36 loss. The company issued its press release and filed its Quarterly Report on Form 10-Q on the same morning.

Net loss was USD 94.78 million, and the loss from operations was USD 97.86 million. Net product revenue was USD 12.9 million, a decrease of USD 1.6 million, or 11.0%, from the third quarter of 2025, according to the filing.

Revenue and Research Spending

The filing states that gross-to-net provisions relative to gross DEXTENZA product sales increased during the quarter, primarily as a result of changes described in the filing. Three specialty distributor customers accounted for specified percentages of the company's total revenue, as detailed in the filing.

Direct Research and Development expenses for products and product candidates were USD 49.4 million, compared with USD 35.9 million in the third quarter of 2025. Interest income was USD 5.0 million, against USD 3.7 million, and interest expense was USD 2.8 million, against USD 3.0 million, an increase of USD 1.3 million and a decrease of USD 0.2 million, respectively.

AXPAXLI Clinical Programs

AXPAXLI is being evaluated in a Phase 3 registrational program for wet age-related macular degeneration and a Phase 3 registrational program for diabetic retinal disease, including non-proliferative diabetic retinopathy. The company also uses its ELUTYX technology in DEXTENZA, a commercial corticosteroid product.

The filing states that AXPAXLI met a pre-specified key secondary endpoint measuring the proportion of subjects who maintained visual acuity at Week 52. To reach at least 300 subjects in aggregate with at least one year of treatment, in line with FDA guidance, and to supplement the 170 subjects who received AXPAXLI in the SOL-1 trial, the company plans an interim safety analysis of the SOL-R trial.

Liquidity and Debt

As of September 30, 2026, the company had cash and cash equivalents of USD 530.6 million and outstanding notes payable with a principal amount of USD 82.5 million Par Value under the Barings Credit Facility.

The filing cautions that there is no assurance research and development can be successfully completed, that products under development can obtain regulatory approval or that any approved products can be commercially successful. It adds that approved products require significant sales, Marketing and distribution support.

The filing states the company believes its current and available cash resources are sufficient to fund the potential FDA approval and launch of AXPAXLI for wet AMD. It adds that additional funding may be required to scale Manufacturing capacity and the commercial team if AXPAXLI is approved.

Ocular Therapeutix Q3 2026 Earnings: Key Takeaways

Ocular Therapeutix reported third quarter 2026 net product revenue of USD 12.87 million and a loss per share of USD 0.42. Net loss was USD 94.78 million, direct research and development expenses were USD 49.4 million, and cash and cash equivalents were USD 530.6 million.